Astec LifeSciences Limited — Updates, 31-07-2026: Press Release
31-07-2026 | 08:56 pm
31-07-2026 | 08:56 pm
Astec LifeSciences reports Q1 FY27 consolidated total income of ₹84.3 Cr, down 8%. The company achieved EBITDA breakeven (₹0.1 Cr) from a ₹10.5 Cr loss, driven by improved margins and capacity utilization. Enterprise Products revenue grew 42%, while CDMO fell 42% against a high base.
No comments yet. Be the first to comment!
